TenNor Therapeutics Secures Significant Funding
TenNor Therapeutics, a clinical stage company focused on developing innovative therapies for infectious diseases, has successfully completed an initial closing of a Series E financing round, totaling more than 300 million RMB. This funding round has attracted investment from the AMR Action Fund alongside existing investors such as Zhongshan Venture Capital. The funds raised will aid in advancing the development and secure regulatory approval for their new drug, rifasutenizol, which holds promise as the first new medication designed specifically for Helicobacter pylori infections in over three decades.
Investors Voice Their Confidence
Expressing gratitude for the financial backing, Dr. Zhenkun Ma, the Founder and CEO of TenNor Therapeutics, stated, “We are excited to receive the support from AMR Action Fund and Zhongshan Venture Capital. Our mission is to tackle the prevalent challenges posed by drug-resistant infections, not only in China but globally. The influx of funding places us in a strong position to acquire regulatory clearance for rifasutenizol, as well as to further push forward another innovative therapy targeting infections related to medical devices.”
Addressing Global Health Issues
According to the CEO of AMR Action Fund, Henry Skinnner, PhD, the crisis of drug-resistant bacterial infections continues to escalate. Data published in reputable journals like The Lancet suggests that antimicrobial resistance could lead to nearly 40 million deaths by mid-century. Skinnner noted that supporting TenNor in their pursuit of unique antibiotic solutions is crucial for saving lives and alleviating the suffering caused by these challenging infections.
TenNor's Innovative Approach
TenNor Therapeutics has established itself as a leader in developing late-stage assets aimed at treating bacterial infections. Cheng Zhang, Chairman of Zhongshan Venture Capital, emphasized the significance of TenNor’s mission: “With a strategy centered on first-line treatments for glaring unmet medical needs, TenNor’s projects carry substantial market potential both nationally and internationally.” The company is dedicated to creating effective therapies for conditions that have historically lacked sufficient treatment options.
Pipeline of Promising Treatments
The company’s flagship candidate, TNP-2198 (rifasutenizol), is positioned as a novel treatment option with a synergistic action mechanism targeting anaerobic and microaerophile bacteria. As the first new drug aimed at Helicobacter pylori in an extensive period, TNP-2198 is an essential component of a larger strategy to conduct widespread screening and eradication of infections that could lead to gastric cancer, particularly in high-risk regions. Currently, TenNor is finalizing a phase 3 clinical trial for this groundbreaking medication.
In tandem with TNP-2198, TenNor is advancing TNP-2092 (rifaquizinone), an innovative triple targeting drug designed to confront the challenges posed by antimicrobial resistance and the persistence of medical device infections. This drug candidate has already undergone six clinical trials in both phase 1 and phase 2 stages and is gearing up for a major phase 3 trial targeting prosthetic joint infections. Significantly, TNP-2092 has also received prestigious designations including Qualified Infectious Disease Product (QIDP), Fast Track, and Orphan Drug from the U.S. FDA.
About TenNor Therapeutics
TenNor Therapeutics is a clinical-stage organization dedicated to discovering and developing novel drug products targeting infections and metabolism-related diseases. They possess a cutting-edge technology platform and a strong portfolio of new drug candidates, all backed by solid global intellectual property protections. The company remains committed to addressing pressing healthcare needs and providing patients with safe, effective treatments for a range of diseases, including but not limited to infections associated with bacterial pathogens.
Frequently Asked Questions
What is the main focus of TenNor Therapeutics?
TenNor Therapeutics specializes in developing new therapies for infectious diseases, particularly those that are resistant to existing treatments.
What will the new funding be used for?
The funding will support the development of rifasutenizol and help secure regulatory approval for innovative therapies targeting bacterial infections.
How is rifasutenizol different from previous treatments?
Rifasutenizol is designed specifically for Helicobacter pylori infections and aims to be the first new drug in this area in 30 years, offering a unique treatment option.
What other products is TenNor developing?
In addition to rifasutenizol, TenNor is also developing TNP-2092, which addresses medical device infections and antimicrobial resistance.
Who are the investors involved in this funding round?
The funding round includes new investment from AMR Action Fund and continuing support from Zhongshan Venture Capital.
